texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician
Request an Appointment

South Texas Clinical Trials

Texas Oncology cancer centers in South Texas participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the South Texas area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the South Texas area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the South Texas area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the South Texas area and talk to you doctor to determine which clinical trial is right for you.

Biliary Cancer

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II

Bladder Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Breast Cancer

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Cervical Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Colon Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Endometrial Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Esophageal Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Gall Bladder Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Gastric Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Head and Neck Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Hematologic

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Weslaco

Phase: IV

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: IV

Liver Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Lung Cancer

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Lymphomas

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I/II

Melanoma

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: IV

Myelodysplastic Syndrome

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Weslaco

Phase: IV

Myelomas

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Weslaco

Phase: IV

Ovarian Cancer

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Pancreatic Cancer

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: II

Prostate Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Rectal Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Renal Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Skin Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Solid Tumors

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Thrombocytopenia

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)

Indication: Thrombocytopenia

Location: Texas Oncology-McAllen

Phase: III

Thyroid Cancer

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Urothelial Cancer

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Waldenström macroglobulinemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Weslaco

Phase: II

Texas Oncology-Harlingen

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Harlingen

Phase: II

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Texas Oncology-McAllen

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-McAllen

Phase: II

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)

Indication: Thrombocytopenia

Location: Texas Oncology-McAllen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Texas Oncology-Weslaco

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Weslaco

Phase: II

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

No Phase

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Title: An Observational, Prospective, Multicenter Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy with Risk of Pneumonitis/ILD

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I

Title: Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph View

Description: A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: I

Phase I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of Avutometinib in Combination with Sotorasib with or without Defactinib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: I/II

Title: Ph1/2a FIH IMT-009 Select Solid Tumors or Lymphomas View

Description: A Phase 1/2a First-in-Human (FIH) Open-Label Dose-Escalation and Dose Expansion Study of the Monoclonal Antibody IMT-009 in Patients with Advanced Solid Tumors or Lymphomas (IMT-009-101)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2 PC14586 TP53 Y220C mut Solid Tumors (PYNNACLE) View

Description: A Phase 1/2 Open-label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics Pharmacodynamics and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) (PMV-586-101)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: I/II

Title: STAR Ph1/2a Study of ART0380 admin Mono + in Combo mSolid Tumors View

Description: A Phase I/IIa Open-label Multi-center Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors (ART0380C001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: I/II

Phase II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Ph2 Futibatinib in FGFR2 Cholangiocarcinoma View

Description: TAS-120-205: Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: II

Title: Ph2 Asciminib (ABL001) CP-CML View

Description: A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Weslaco

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: II

Title: Ph2 Study of TTX-030 treatment of patients not previously treated for met Pancreatic Adenocarcinoma View

Description: An open-label multicenter 3-arm randomized Phase 2 study to assess the efficacy and safety of TTX-030 and chemotherapy with or without budigalimab compared to chemotherapy alone for the treatment of patients not previously treated for metastatic pancreatic adenocarcinoma (TTX-030-003)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Harlingen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-McAllen

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Waldenström macroglobulinemia

Location: Texas Oncology-Weslaco

Phase: II

Phase II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-McAllen

Phase: II/III

Title: STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2) View

Description: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011)

Indication: Urothelial Cancer

Location: Texas Oncology-Weslaco

Phase: II/III

Phase III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4) View

Description: EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03) View

Description: A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR: PH1/3 Biomarker unresectable stg3 NSCLC View

Description: A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 DXd +Pembro NSCLC (Tropion-LUNG08) PD-L1 >50% View

Description: A Randomized Open-label Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naive Subjects with Advanced or Metastatic PD-L1 High (TPS>=50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08)(Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects with Advanced or Metastatic NSCLC Without Actionable Genomic Alterations)(DS1062-A-U304)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 HLX10 Carbo Cisp-Etop LS-SCLC View

Description: A Randomized Double-Blind International Multicenter Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC) (HLX10-020-SCLC302)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR View

Description: A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Ph3 Dato-Dxd Pembro PD-L1 <50% NSCLC (TL07) View

Description: A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab with or Without Platinum Chemotherapy in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07) (DS1062-A-U303)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)

Indication: Thrombocytopenia

Location: Texas Oncology-McAllen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertion Mutation

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: III

Title: Randomized, Open-Label Study of the BRIA-IMT Regimen and Check Point Inhibitor vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: III

Phase IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Biliary Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Breast Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Cervical Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Colon Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Endometrial Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Esophageal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gall Bladder Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Gastric Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Head and Neck Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Hematologic

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Leukemia

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Liver Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Lung Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Melanoma

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Myelomas

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Ovarian Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Pancreatic Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Prostate Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Rectal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Renal Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Skin Cancer

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Solid Tumors

Location: Texas Oncology-Weslaco

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Harlingen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-McAllen

Phase: IV

Title: CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test View

Description: Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001)

Indication: Thyroid Cancer

Location: Texas Oncology-Weslaco

Phase: IV